News from AHA 2024: KRAKEN trial, Muvalaplin, Lp(a)

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Obicetrapib lowers LDL-c on top of other lipid lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid lowering therapies in HeFH
Heart Matters
Obicetrapib lowers LDL-c on top of other lipid lowering therapies in HeFH
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Tirzepatide reduces HF events in patients with HFpEF and obesity
Tirzepatide reduces HF events in patients with HFpEF and obesity
Heart Matters
Tirzepatide reduces HF events in patients with HFpEF and obesity
- Milton Packer, MD
Acoramidis reduces all-cause mortality in ATTR-CM
Acoramidis reduces all-cause mortality in ATTR-CM
Heart Matters
Acoramidis reduces all-cause mortality in ATTR-CM
- Daniel Judge, MD
Effect of decision support system on early optimization of lipid-lowering therapy
Effect of decision support system on early optimization of lipid-lowering therapy
Heart Matters
Effect of decision support system on early optimization of lipid-lowering therapy
- Kausik Ray, MBChB, MD, MPhil

Promising results with oral Lp(a) inhibitor in phase 2 trial